ENGAGE注册研究:Endurant支架移植物用于EVAR的五年结局
ENGAGE注册研究纳入2009年3月至2011年4月全球30个国家79个中心的1263例腹主动脉瘤患者,评估Endurant支架移植物行标准EVAR的五年结局。五年总生存率为67.4%,无动脉瘤相关死亡率为97.8%,无破裂、二次干预和转为开放手术的比例分别为98.6%、84.3%和97.9%,提示真实世界人群中持续安全有效。
要点
- ENGAGE注册五年随访显示Endurant支架行EVAR的动脉瘤相关死亡率低、耐久性良好。
- 五年无二次干预率为84.3%,提示部分患者仍需再干预,应坚持长期随访。
- 17.8%患者植入超出器械使用说明,但整体结局仍稳定。
核心结论
- ENGAGE注册五年随访显示,Endurant支架移植物在国际真实世界队列中具有持续的安全性、有效性和耐久性。
研究设计与样本
- ENGAGE注册研究为国际多中心注册研究,共纳入1263例腹主动脉瘤患者,来自30个国家79个中心,入组时间为2009年3月至2011年4月,旨在报告五年标准EVAR结局。
主要发现
- 五年Kaplan-Meier总生存率为67.4%,无动脉瘤相关死亡率为97.8%。
- 五年无动脉瘤破裂率为98.6%,无二次干预率为84.3%,无转为开放手术率为97.9%。
- 五年无IA型内漏率为95.2%,无III型内漏率为97.4%。
- 五年时89.4%的患者瘤囊直径缩小≥5 mm或保持稳定。
- 入组患者中15.2%瘤径>7 cm,12.0%近端瘤颈长度<15 mm,10.2%肾下瘤颈角度>60°,17.8%植入超出器械使用说明。
临床怎么用
- 对于接受Endurant支架行EVAR的腹主动脉瘤患者,五年随访数据支持其持久性,但仍需关注二次干预风险并坚持长期影像随访。
局限性
- 原文未报告该研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Endovascular abdominal aortic aneurysm repair (EVAR) is commonly used to treat abdominal aortic aneurysm (AAA). However, the incidence of long-term complications and the need for re-interventions after EVAR remain a concern. Newer generation stent grafts have encouraging short and mid-term outcomes, but thorough analysis of their long-term performance is necessary. METHODS: The ENGAGE registry includes a total of 1263 patients with AAA enrolled from March 2009 to April 2011 at 79 centres across 30 countries. The aim of this study is to present standard EVAR outcomes in the registry after five years. RESULTS: A significant proportion of the ENGAGE patients presented with challenging features, such as 15.2% with an AAA diameter >7 cm, 12.0% with proximal neck lengths <15 mm, and 10.2% with infrarenal neck angles >60°. Of the 1263 enrolled subjects, 17.8% were implanted outside of the instructions for use for the device. At the five year follow up, the Kaplan-Meier overall survival rate was 67.4% and the freedom from aneurysm related mortality was 97.8%. Freedom from aneurysm rupture, secondary procedures, and conversion to open repair at five years were 98.6%, 84.3%, and 97.9% respectively. The five year freedom from type IA endoleaks was 95.2% and for type III endoleaks 97.4%. Aneurysm sac diameter at five years was observed to have either decreased ≥5 mm in diameter or remained stable in 89.4% of the patients. CONCLUSION: Five year follow up of patients in the ENGAGE registry demonstrates sustained safety, effectiveness, and durability in an international cohort that is reflective of real world experience. Additional follow up is expected through to 10 years.
引用
- Teijink JAW, Power AH, Böckler D, et al. Editor's Choice - Five Year Outcomes of the Endurant Stent Graft for Endovascular Abdominal Aortic Aneurysm Repair in the ENGAGE Registry. Eur J Vasc Endovasc Surg. 2019. PMID: 31235305. doi:10.1016/j.ejvs.2019.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。